FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559679969> ?p ?o ?g. }

• W2559679969 endingPage "2805" @default.
• W2559679969 startingPage "2795" @default.
• W2559679969 abstract "Abstract Purpose: Determine the roles of the PI3K isoforms p110α and p110β in PTEN-deficient, estrogen receptor α (ER)-positive breast cancer, and the therapeutic potential of isoform-selective inhibitors. Experimental Design: Anti-estrogen-sensitive and -resistant PTEN-deficient, ER+ human breast cancer cell lines, and mice bearing anti-estrogen–resistant xenografts were treated with the anti-estrogen fulvestrant, the p110α inhibitor BYL719, the p110β inhibitor GSK2636771, or combinations. Temporal response to growth factor receptor–initiated signaling, growth, apoptosis, predictive biomarkers, and tumor volumes were measured. Results: p110β primed cells for response to growth factor stimulation. Although p110β inhibition suppressed cell and tumor growth, dual targeting of p110α/β enhanced apoptosis and provided sustained tumor response. The growth of anti-estrogen–sensitive cells was inhibited by fulvestrant, but fulvestrant inconsistently provided additional therapeutic effects beyond PI3K inhibition alone. Treatment-induced decreases in phosphorylation of AKT and Rb were predictive of therapeutic response. Short-term drug treatment induced tumor cell apoptosis and proliferative arrest to induce tumor regression, whereas long-term treatment only suppressed proliferation to provide durable regression. Conclusions: p110β is the dominant PI3K isoform in PTEN-deficient, ER+ breast cancer cells. Upon p110β inhibition, p110α did not induce significant reactivation of AKT, but combined targeting of p110α/β most effectively induced apoptosis in vitro and in vivo and provided durable tumor regression. Because apoptosis and tumor regression occurred early but not late in the treatment course, and proliferative arrest was maintained throughout treatment, p110α/β inhibitors may be considered short-term cytotoxic agents and long-term cytostatic agents. Clin Cancer Res; 23(11); 2795–805. ©2016 AACR." @default.
• W2559679969 created "2016-12-08" @default.
• W2559679969 creator A5011688597 @default.
• W2559679969 creator A5016875323 @default.
• W2559679969 creator A5021770361 @default.
• W2559679969 creator A5023196429 @default.
• W2559679969 creator A5028561152 @default.
• W2559679969 creator A5028605567 @default.
• W2559679969 creator A5029866914 @default.
• W2559679969 creator A5076719905 @default.
• W2559679969 creator A5080163243 @default.
• W2559679969 date "2017-05-31" @default.
• W2559679969 modified "2023-10-11" @default.
• W2559679969 title "Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer" @default.
• W2559679969 cites W1693454377 @default.
• W2559679969 cites W1963781106 @default.
• W2559679969 cites W1974128502 @default.
• W2559679969 cites W1975570973 @default.
• W2559679969 cites W1979340580 @default.
• W2559679969 cites W1986976113 @default.
• W2559679969 cites W1988864736 @default.
• W2559679969 cites W1990762130 @default.
• W2559679969 cites W2012652051 @default.
• W2559679969 cites W2014001512 @default.
• W2559679969 cites W2016869069 @default.
• W2559679969 cites W2022742795 @default.
• W2559679969 cites W2033672070 @default.
• W2559679969 cites W2040762618 @default.
• W2559679969 cites W2046410395 @default.
• W2559679969 cites W2046584993 @default.
• W2559679969 cites W2067176508 @default.
• W2559679969 cites W2071463092 @default.
• W2559679969 cites W2087693130 @default.
• W2559679969 cites W2088793241 @default.
• W2559679969 cites W2095971747 @default.
• W2559679969 cites W2096283457 @default.
• W2559679969 cites W2101982508 @default.
• W2559679969 cites W2106036365 @default.
• W2559679969 cites W2108068107 @default.
• W2559679969 cites W2108401385 @default.
• W2559679969 cites W2115950635 @default.
• W2559679969 cites W2116201594 @default.
• W2559679969 cites W2118728607 @default.
• W2559679969 cites W2118934356 @default.
• W2559679969 cites W2118978588 @default.
• W2559679969 cites W2124593509 @default.
• W2559679969 cites W2126783165 @default.
• W2559679969 cites W2128613144 @default.
• W2559679969 cites W2132141505 @default.
• W2559679969 cites W2134629247 @default.
• W2559679969 cites W2138264320 @default.
• W2559679969 cites W2150174916 @default.
• W2559679969 cites W2150798124 @default.
• W2559679969 cites W2153096480 @default.
• W2559679969 cites W2155228605 @default.
• W2559679969 cites W2156918228 @default.
• W2559679969 cites W2166188515 @default.
• W2559679969 cites W2168286074 @default.
• W2559679969 cites W2168866504 @default.
• W2559679969 cites W2170908060 @default.
• W2559679969 cites W2312186855 @default.
• W2559679969 doi "https://doi.org/10.1158/1078-0432.ccr-15-2764" @default.
• W2559679969 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5449270" @default.
• W2559679969 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27903677" @default.
• W2559679969 hasPublicationYear "2017" @default.
• W2559679969 type Work @default.
• W2559679969 sameAs 2559679969 @default.
• W2559679969 citedByCount "25" @default.
• W2559679969 countsByYear W25596799692017 @default.
• W2559679969 countsByYear W25596799692018 @default.
• W2559679969 countsByYear W25596799692019 @default.
• W2559679969 countsByYear W25596799692020 @default.
• W2559679969 countsByYear W25596799692021 @default.
• W2559679969 countsByYear W25596799692022 @default.
• W2559679969 countsByYear W25596799692023 @default.
• W2559679969 crossrefType "journal-article" @default.
• W2559679969 hasAuthorship W2559679969A5011688597 @default.
• W2559679969 hasAuthorship W2559679969A5016875323 @default.
• W2559679969 hasAuthorship W2559679969A5021770361 @default.
• W2559679969 hasAuthorship W2559679969A5023196429 @default.
• W2559679969 hasAuthorship W2559679969A5028561152 @default.
• W2559679969 hasAuthorship W2559679969A5028605567 @default.
• W2559679969 hasAuthorship W2559679969A5029866914 @default.
• W2559679969 hasAuthorship W2559679969A5076719905 @default.
• W2559679969 hasAuthorship W2559679969A5080163243 @default.
• W2559679969 hasBestOaLocation W25596799691 @default.
• W2559679969 hasConcept C121608353 @default.
• W2559679969 hasConcept C126322002 @default.
• W2559679969 hasConcept C134018914 @default.
• W2559679969 hasConcept C190283241 @default.
• W2559679969 hasConcept C2777164284 @default.
• W2559679969 hasConcept C2777609662 @default.
• W2559679969 hasConcept C2780482068 @default.
• W2559679969 hasConcept C2781465904 @default.
• W2559679969 hasConcept C502942594 @default.
• W2559679969 hasConcept C530470458 @default.
• W2559679969 hasConcept C55493867 @default.
• W2559679969 hasConcept C71924100 @default.

• next